NASDAQ
0.60USD
+0.01 (+1.49%)
We have scored 17 news catalysts on Humacyte, Inc. (HUMA) over the past 12 months. The biggest single-day move next to one of them came Apr 9, 2026, when HUMA closed −6.8%: “Did The Trade Desk, Inc. Insiders Breach their Fiduciary Duties to Shareholders?”. Coverage across the window leans negative (average ticker sentiment −0.18). Most of the impact sits in price momentum and forward growth expectations.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Latest scored catalyst for HUMA: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Market cap
101.6M
P/E
—
EPS
—
Beta
2.45
52W range
0.526-2.55
Day range
0.58–0.61
Open
0.59
Prev close
0.60
Volume
3M
Avg volume
9.8M
Dividend
0.00
IPO
2020-12-01
Humacyte, Inc. focuses on developing and manufacturing readily available, implantable human tissues engineered in a laboratory setting. These bioengineered tissues are designed to treat a wide array of diseases and conditions across various anatomical locations and therapeutic fields. The company employs its distinct scientific and proprietary technology platform to produce human acellular vessels (HAVs). These investigational HAVs are specifically crafted for universal compatibility, enabling easy implantation into any patient without inducing an immune rejection or an adverse foreign body response. Humacyte is currently building a pipeline of HAVs targeting the substantial market for vascular repair, reconstruction, and replacement. This includes applications such as treating vascular trauma, providing arteriovenous access for hemodialysis, addressing peripheral arterial disease, and facilitating coronary artery bypass grafting. Furthermore, the company is exploring the use of its HAVs for pediatric heart surgeries and for cellular therapeutic delivery, including the transplantation of pancreatic islet cells to manage Type 1 diabetes. Founded in 2004, Humacyte maintains its headquarters in Durham, North Carolina.
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Humacyte, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
